Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs SCB 2019 (Primary) ; Alum; AS03A; CpG 1018
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Clover Biopharmaceuticals
- 17 Feb 2022 Status changed from active, no longer recruiting to completed.
- 04 Sep 2021 Results assessing persistence of antibodies up to 6 months after vaccination, and cross-neutralization titers against three Variants of Concern, published in the Journal of Infectious Diseases
- 03 Feb 2021 Interim results (data cutoff date: 23 Oct 2020) from first stage (dose-finding and adjuvant justification) from this trial done to assess safety, tolerability, and immunogenicity of three doses published in the Internet Document